Avanir Pharmaceuticals

Encouraging data reported from phase I study of asthma/allergy drug

Published in Pharma Law Weekly, June 1st, 2004

Avanir Pharmaceuticals (AVN) announced the completion of the initial phase I clinical trial for its experimental asthma/allergy drug, AVP 13358.

The study included 54 healthy volunteers and was intended to assess safety, tolerability, and pharmacokinetics following a single oral administration. Results from the study suggest AVP 13358 was well tolerated at all doses. The study also demonstrated AVP 13358 was detectable in the bloodstream at all doses administered and remains in circulation long enough to allow once or twice daily dosing.

"We are very pleased to see the level of exposure, tolerability and the promising pharmacokinetic profile that our...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry